Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levofloxacin
Drug ID BADD_D01275
Description Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin].[A190663] It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin[A190663] and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).[L11638] Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.[A190663]
Indications and Usage For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.
Marketing Status Prescription; Discontinued
ATC Code J01MA12; S01AE05
DrugBank ID DB01137
KEGG ID D00588
MeSH ID D064704
PubChem ID 149096
TTD Drug ID D02RSN
NDC Product Code 68071-3093; 54288-140; 65862-538; 63415-0056; 68382-989; 17478-106; 70518-0932; 69097-282; 43063-457; 0143-9722; 61919-704; 80425-0076; 63187-384; 63323-355; 68083-415; 55111-279; 55150-156; 71335-0965; 67296-0897; 0904-6351; 70518-0968; 0781-5792; 67296-0972; 55154-5897; 42571-168; 51407-429; 50090-4572; 71335-0593; 63629-8070; 53002-3350; 68071-4512; 63187-514; 69097-289; 52343-120; 13668-083; 52343-121; 67296-1641; 55150-157; 0781-5791; 36000-295; 80425-0007; 68071-4926; 55111-281; 71205-234; 50090-1228; 65977-0039; 50090-2001; 67296-0975; 53002-2350; 55154-5898; 36000-294; 44567-436; 0143-9720; 44567-437; 63187-003; 68071-2074; 0143-9316; 68071-1860; 63187-833; 69097-287; 53002-2582; 53104-7550; 55111-280; 43063-637; 36000-048; 50383-286; 68071-4874; 68071-3166; 68180-241; 43063-459; 58118-1022; 68071-4726; 25021-132; 71335-0327; 71335-0133; 68071-4875; 67296-0977; 42708-122; 43063-638; 51407-430; 68180-242; 0527-1948; 0143-9721; 63187-925; 53069-0600; 68083-414; 71335-0391; 67296-1393; 50090-4797; 63187-004; 71335-0794; 68083-395; 50090-2498; 68071-3236; 71335-0434; 65841-692; 67296-1351; 71335-0380; 70934-094; 72578-098; 68071-4738; 43235-0007; 65841-691; 36000-296; 68071-3218; 63629-7681; 63187-438; 67296-0985; 31722-723; 65862-488; 65862-536; 54348-611; 50090-3214; 67296-1535; 72578-099; 0143-9317; 66721-200; 70518-2249; 61919-440; 43063-796; 53002-1350; 70934-050; 68788-6938; 0409-0528; 33342-023; 0781-5790; 67296-0744; 72578-100; 65841-693; 17478-107; 51407-428; 68083-416; 50090-4573; 49587-102; 68071-4900; 31722-722; 13668-084; 63629-4843; 61919-426; 65862-537; 70518-0453; 71205-002; 13668-082; 67296-1400; 68788-6816; 71335-0525; 80425-0009; 50090-4928; 70934-392; 67296-1546; 70771-1079; 52343-119; 45865-758; 36000-046; 44567-435; 55700-729; 0904-6353; 61919-987; 71335-1277; 31722-721; 68083-394; 68180-240; 67296-1325; 80425-0008; 72189-338; 36000-045; 67296-0998; 70518-2145; 71205-058; 72789-085; 80425-0077; 33342-022; 53002-1391; 0904-6352; 55525-0001; 36000-047; 71335-1208; 0143-9315; 33342-021
Synonyms Levofloxacin | Ofloxacin, (S)-Isomer | Levofloxacin Anhydrous | Anhydrous, Levofloxacin | Quixin | Levaquin
Chemical Information
Molecular Formula C18H20FN3O4
CAS Registry Number 100986-85-4
SMILES CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.000693%Not Available
Apparent death08.01.03.0620.000173%Not Available
Quality of life decreased13.18.01.013--Not Available
Skin plaque23.03.03.0440.000173%Not Available
Ocular pemphigoid23.03.01.030; 10.04.04.015; 06.04.05.0300.000347%Not Available
Capillaritis24.05.02.017; 23.06.02.0070.000173%Not Available
Ligament pain15.07.02.0070.000173%Not Available
Tubulointerstitial nephritis and uveitis syndrome20.05.02.004; 10.02.01.065; 06.04.03.0060.000260%Not Available
Band sensation17.16.01.0040.000347%Not Available
Respiratory muscle weakness22.09.01.004; 17.05.03.017; 15.05.06.0030.000693%Not Available
Crystal nephropathy14.11.01.035; 20.05.03.0160.001127%Not Available
Hyporesponsive to stimuli17.02.05.0570.000260%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000520%Not Available
Meniscus injury15.07.03.006; 12.04.03.0080.000780%Not Available
Postural tremor17.01.06.0090.000347%Not Available
Small fibre neuropathy17.09.03.021; 14.07.04.007; 05.07.04.0070.000260%Not Available
Tendon discomfort15.07.01.0120.000607%Not Available
Internal haemorrhage24.07.01.072--Not Available
Nodular rash23.03.13.0210.000433%Not Available
Urinary tract discomfort20.02.03.0170.000260%Not Available
The 30th Page    First    Pre   30    Total 30 Pages